$MYO
MYOMO, INC.

2021 Form 10-K Financial Statement

#000156459022009827 Filed on March 11, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $13.86M $3.790M $7.583M
YoY Change 82.72% 149.23% 97.6%
Cost Of Revenue $112.9K $1.008M $2.600M
YoY Change -95.66% 137.26% 83.03%
Gross Profit $13.74M $2.782M $4.983M
YoY Change 175.81% 153.86% 106.17%
Gross Profit Margin 99.19% 73.42% 65.71%
Selling, General & Admin $18.02M $4.050M $13.82M
YoY Change 30.45% 25.23% 20.54%
% of Gross Profit 131.14% 145.57% 277.27%
Research & Development $2.557M $1.669M
YoY Change 53.21% -4.59%
% of Gross Profit 18.61% 33.5%
Depreciation & Amortization $146.0K $25.65K $105.4K
YoY Change 38.54% 4.95% 10.78%
% of Gross Profit 1.06% 0.92% 2.11%
Operating Expenses $20.58M $4.469M $15.49M
YoY Change 32.9% 21.55% 17.21%
Operating Profit -$6.837M -$1.687M -$10.50M
YoY Change -34.9% -34.65% -2.71%
Interest Expense -$15.34K -$1.870K -$352.0K
YoY Change -95.64% -98.97% 30777.19%
% of Operating Profit
Other Income/Expense, Net -$15.34K -$1.061M
YoY Change -98.55% -1394.27%
Pretax Income -$10.28M -$1.701M -$11.56M
YoY Change -11.07% -38.39% 7.94%
Income Tax $88.93K -$2.850K $0.00
% Of Pretax Income
Net Earnings -$10.37M -$1.698M -$11.56M
YoY Change -10.31% -38.5% 7.94%
Net Earnings / Revenue -74.85% -44.81% -152.49%
Basic Earnings Per Share -$1.89
Diluted Earnings Per Share -$1.779M -$368.0K -$3.473M
COMMON SHARES
Basic Shares Outstanding 5.830M
Diluted Shares Outstanding 5.830M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.52M $12.24M $12.24M
YoY Change 26.82% 174.13% 174.13%
Cash & Equivalents $15.52M $12.24M $12.24M
Short-Term Investments
Other Short-Term Assets $894.5K $572.7K $572.7K
YoY Change 56.19% -30.18% -30.18%
Inventory $808.3K $707.1K $707.1K
Prepaid Expenses
Receivables $1.960M $924.9K $924.9K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $19.19M $14.45M $14.45M
YoY Change 32.82% 134.91% 134.91%
LONG-TERM ASSETS
Property, Plant & Equipment $908.2K $95.02K $263.8K
YoY Change 244.26% -38.68% 70.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $908.2K $263.8K $263.8K
YoY Change 244.27% -41.27% -41.27%
TOTAL ASSETS
Total Short-Term Assets $19.19M $14.45M $14.45M
Total Long-Term Assets $908.2K $263.8K $263.8K
Total Assets $20.10M $14.71M $14.71M
YoY Change 36.61% 122.92% 122.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $723.4K $180.5K $180.5K
YoY Change 300.75% -59.9% -59.9%
Accrued Expenses $3.367M $2.687M $2.687M
YoY Change 25.33% 108.54% 108.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $4.283M $2.870M $2.870M
YoY Change 49.26% -26.11% -26.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $402.9K $118.1K $274.7K
YoY Change 46.66% 7770.67% 18213.33%
Total Long-Term Liabilities $402.9K $118.1K $274.7K
YoY Change 46.66% -86.72% -69.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.283M $2.870M $2.870M
Total Long-Term Liabilities $402.9K $118.1K $274.7K
Total Liabilities $4.686M $3.144M $3.144M
YoY Change 49.04% -34.13% -34.13%
SHAREHOLDERS EQUITY
Retained Earnings -$67.69M
YoY Change 20.6%
Common Stock $79.27M
YoY Change 36.78%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $15.41M $11.57M $11.57M
YoY Change
Total Liabilities & Shareholders Equity $20.10M $14.71M $14.71M
YoY Change 36.61% 122.92% 122.92%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$10.37M -$1.698M -$11.56M
YoY Change -10.31% -38.5% 7.94%
Depreciation, Depletion And Amortization $146.0K $25.65K $105.4K
YoY Change 38.54% 4.95% 10.78%
Cash From Operating Activities -$9.548M -$1.154M -$9.033M
YoY Change 5.7% -56.35% -12.66%
INVESTING ACTIVITIES
Capital Expenditures $326.5K -$15.46K $45.75K
YoY Change 613.55% 12.6% -12.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$326.5K -$15.46K -$45.75K
YoY Change 613.55% 12.6% -12.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.100M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.17M 18.93K 16.78M
YoY Change -21.53% -99.32% 101.73%
NET CHANGE
Cash From Operating Activities -9.548M -1.154M -9.033M
Cash From Investing Activities -326.5K -15.46K -45.75K
Cash From Financing Activities 13.17M 18.93K 16.78M
Net Change In Cash 3.283M -1.151M 7.701M
YoY Change -57.37% -939.25% -471.06%
FREE CASH FLOW
Cash From Operating Activities -$9.548M -$1.154M -$9.033M
Capital Expenditures $326.5K -$15.46K $45.75K
Free Cash Flow -$9.874M -$1.139M -$9.079M
YoY Change 8.76% -56.71% -12.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M3D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M29D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M19D
CY2021 myo Product Warranty Period
ProductWarrantyPeriod
P3Y
CY2016 myo Product Warranty Period
ProductWarrantyPeriod
P1Y
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M29D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2021 dei Auditor Firm
AuditorFirmId
688
CY2021 dei Auditor Name
AuditorName
Marcum, LLP
CY2021 dei Auditor Location
AuditorLocation
New York, NY, USA
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15524378
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12241261
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1960037
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
924916
CY2021Q4 us-gaap Inventory Net
InventoryNet
808308
CY2020Q4 us-gaap Inventory Net
InventoryNet
707114
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
894494
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
572684
CY2021Q4 us-gaap Assets Current
AssetsCurrent
19187217
CY2020Q4 us-gaap Assets Current
AssetsCurrent
14445975
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
632906
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
168784
CY2021Q4 us-gaap Assets
Assets
20095412
CY2020Q4 us-gaap Assets
Assets
14709782
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2848904
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
333380
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18289
CY2020Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2512
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
155148
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1495
CY2020Q4 us-gaap Liabilities
Liabilities
3144408
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12690
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
457
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
79273964
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60677
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12690
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78062222
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67689893
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15409131
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11565374
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20095412
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14709782
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
218803
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-709222
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10283401
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11563911
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
88928
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-11563911
CY2020 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
670632
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12234543
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3329868
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.67
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10372329
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-47987
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12690
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47987
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10420316
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11576601
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6425885
CY2020 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
1499370
CY2020 myo Prior Period Offering Cost From Sale Of Shares
PriorPeriodOfferingCostFromSaleOfShares
161253
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13475535
CY2020 myo Proceeds From Issuance Of Prefunded Warrants In Conjunction With Public Offering
ProceedsFromIssuanceOfPrefundedWarrantsInConjunctionWithPublicOffering
48
CY2020 myo Proceeds From Issuances Under At Market Sales Facility Value
ProceedsFromIssuancesUnderAtMarketSalesFacilityValue
4917575
CY2020 myo Issuances Of Common Stock Value Repay Debt
IssuancesOfCommonStockValueRepayDebt
2150405
CY2020 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
161250
CY2020 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
489
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1852
CY2020 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
614302
CY2020 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
-12690
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-11563911
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11565374
CY2021 myo Common Stock Issued For Warrants Exercised Net Of Offering Costs
CommonStockIssuedForWarrantsExercisedNetOfOfferingCosts
349400
CY2021 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
12067865
CY2021 myo Proceeds From Issuances Under At Market Sales Facility Value
ProceedsFromIssuancesUnderAtMarketSalesFacilityValue
1099800
CY2021 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
-47987
CY2021 us-gaap Profit Loss
ProfitLoss
-10372329
CY2020 us-gaap Profit Loss
ProfitLoss
-11563911
CY2021 us-gaap Depreciation
Depreciation
145995
CY2020 us-gaap Depreciation
Depreciation
105382
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1096408
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
614302
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-202
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-547
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9839
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
218803
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
161869
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
189968
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3288
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-709222
CY2020 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
122706
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
19929
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
18446
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1046282
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
522944
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
118222
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
271545
CY2021 myo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
323644
CY2020 myo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-248464
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-57987
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1113235
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1217929
CY2021 myo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-92525
CY2020 myo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1365
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2512
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-401
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-118060
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
118060
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
326462
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9547695
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9032896
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45752
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-326462
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45752
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
1703552
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
255533
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13504812
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1855
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
161298
CY2021 myo Proceeds From At The Market Offering Net Of Offering Costs
ProceedsFromAtTheMarketOfferingNetOfOfferingCosts
1099801
CY2020 myo Proceeds From At The Market Offering Net Of Offering Costs
ProceedsFromAtTheMarketOfferingNetOfOfferingCosts
5049551
CY2020 myo Proceeds From Payments Under Grants
ProceedsFromPaymentsUnderGrants
25852
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-10392
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1122
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3283117
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7700806
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15524378
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12241261
CY2020 myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
2743
CY2020 us-gaap Property Plant And Equipment Transfers And Changes
PropertyPlantAndEquipmentTransfersAndChanges
2514
CY2020 myo Deferred Issuance Costs To Additional Paid In Capital Paid In Prior Period
DeferredIssuanceCostsToAdditionalPaidInCapitalPaidInPriorPeriod
161253
CY2020 us-gaap Stock Issued1
StockIssued1
2150405
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
654091
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
172072
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 1 — Description of Business</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics (“O&amp;P”) providers for which they are paid a fee.  The Company sells the product to O&amp;P providers around the world, the Veterans Health Administration (VA), and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to an amended and restated certificate of incorporation, the Company is authorized to issue up to 75,000,000 shares of stock, consisting of 65,000,000 shares of common stock, par value $0.0001 and 10,000,000 shares of undesignated Preferred Stock, par value of $0.0001.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-on Public Offering</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed a follow-on offering of 1,660,000 shares of its common stock and 1,660,000 investor warrants to purchase one share of the Company’s common stock at a combined offering price of $7.00 per share (“February 2020 Offering”).  In addition, the Company sold 483,000 pre-funded warrants and 483,000 investor warrants to purchase one share of the Company’s common stock at a combined offering price of $6.999 per share. The offering generated approximately $13.5 million in net proceeds to the Company.  See Note 8 – Preferred and Common Stock, for further information.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shelf Registration Statement</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 14, 2021, the Company filed a Registration Statement on Form S-3 (the “Shelf”) with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, warrants and/or units or any combination thereof the Company (collectively, the “Securities”) having an aggregate price of up to $100 million, subject to the limitations of the Shelf. On June 25, 2021, the Company entered into an At Market Issuance Sales Agreement (the “ATM”) with Alliance Global Partners “(AGP”), as sales agent, to provide for the offering, issuance and sale by the Company of up to an aggregate amount of $15 million of the Company’s common stock from time to time in “at-the-market” offerings under the Shelf and subject to the limitations thereof. The Company shall pay to the sales agent cash commissions of 3.0% of the gross proceeds of sales of common stock under the ATM. See Note 8 – Preferred and Common Stock, for further information.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net losses of approximately $10,372,000 and $11,564,000 during the years ended December 31, 2021 and 2020, respectively, and has an accumulated deficit of approximately $78,062,000 and $67,690,000<span style="font-size:11pt;"> </span>at December 31, 2021 and 2020, respectively. Cash used in operating activities was approximately $9,548,000<span style="font-size:11pt;"> </span>and $9,033,000<span style="font-size:11pt;"> </span>for the years ended December 31, 2021 and 2020, respectively.  The Company has historically funded its operations through financing activities, including raising equity and debt capital.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-size:10pt;font-family:Times New Roman;">Management’s operating plans are primarily focused on scaling up its operations, increasing the proportion of patients carrying commercial health insurance with payers that have historically reimbursed for the Company’s products, and continued work with the Centers for Medicare and Medicaid Services, or CMS, and their billing contractors regarding reimbursement of its products. In addition, the Company believes that it has access to capital resources through payment of a license fee associated with the Company’s entry into a joint venture and technology license agreement with Beijing Ryzur Medical Investment Co. Ltd., possible public or private equity offerings, including usage of its ATM facility (approximately $13.7 million remaining availability as of December 31, 2021), exercises of outstanding warrants, additional debt financings, or other means.  Additional debt financing may contain </span></p> <p style="margin-bottom:0pt;margin-top:12pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;">t</span><span style="font-size:10pt;font-family:Times New Roman;">erms that are not favorable to the Company or its stockholders. </span><span style="font-size:10pt;font-family:Times New Roman;">Historical losses, quantitatively, give rise to substantial doubt regarding </span><span style="font-size:10pt;font-family:Times New Roman;">the Company’s ability to continue to operate as a </span><span style="font-size:10pt;font-family:Times New Roman;">going concern. However, based on the company's latitude as to the timing and amount of certain expenses, and its current cash position, the </span><span style="font-size:10pt;font-family:Times New Roman;">C</span><span style="font-size:10pt;font-family:Times New Roman;">ompany believes that substantial doubt</span><span style="font-size:10pt;font-family:Times New Roman;"> about its liquidity</span><span style="font-size:10pt;font-family:Times New Roman;"> is mitigated</span><span style="font-size:10pt;font-family:Times New Roman;"> </span><span style="font-size:10pt;font-family:Times New Roman;">for at least twelve months from the issuance date of</span><span style="font-size:10pt;font-family:Times New Roman;"> these financial statements</span><span style="font-size:10pt;font-family:Times New Roman;">.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, the Company completed a transaction to incentivize the exercise of the warrants issued in its February 2020 Offering by reducing the exercise price to $5.00 per share.  The Company generated $4.8 million of net proceeds from this transaction (See Note 10 – Warrants). In addition, the Company generated net proceeds of $1.1 million from sales of common stock under ATM facility during 2021 (See Note 8 – Preferred and Common Stock).  Based upon its expected cash flows, including the expected payment of the license fee by the joint venture partner in China, and net proceeds from the aforementioned transactions, the Company believes that its available cash will fund its operations for at least the next twelve months from the issuance date of these financial statements. <span style="font-family:Calibri;font-size:11pt;"> </span>  </p>
CY2021Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
75000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10372000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-11564000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78062000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67690000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9548000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9033000
CY2021Q4 myo Remaining Availability Under Offerings
RemainingAvailabilityUnderOfferings
13700000
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.00
CY2021Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
4800000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1100000
CY2021 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2020 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2021 myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.39
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:8pt;margin-bottom:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s estimates include the allowance for doubtful accounts, deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.</p>
CY2021 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.40
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
1500
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
4000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13856374
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7583371
CY2021 myo Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Ultimate Settlement
IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponUltimateSettlement
0.50
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1017841
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3009845
CY2021 us-gaap Advertising Expense
AdvertisingExpense
3587300
CY2020 us-gaap Advertising Expense
AdvertisingExpense
841300
CY2021Q4 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
640000
CY2021Q4 myo Accrued Liabilities Customer Deposit
AccruedLiabilitiesCustomerDeposit
192501
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
176082
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
40682
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
23161
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
18000
CY2021Q4 myo Inventory Rental Units
InventoryRentalUnits
62531
CY2020Q4 myo Inventory Rental Units
InventoryRentalUnits
62531
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
584996
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
603443
CY2021Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
846770
CY2020Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
724656
CY2021Q4 myo Inventory Reserve For Rental Units
InventoryReserveForRentalUnits
38462
CY2020Q4 myo Inventory Reserve For Rental Units
InventoryReserveForRentalUnits
17542
CY2021Q4 us-gaap Inventory Net
InventoryNet
808308
CY2020Q4 us-gaap Inventory Net
InventoryNet
707114
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
707183
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
382468
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
431894
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
287445
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
275289
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
95023
CY2021 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
146000
CY2020 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
105400
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
723352
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
180499
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2188869
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1843402
CY2021Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
108417
CY2020Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
92399
CY2021Q4 myo Deferred Payroll Taxes Under Cares Act
DeferredPayrollTaxesUnderCARESAct
113423
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
176281
CY2020Q4 myo Deferred Payroll Taxes Under Cares Act
DeferredPayrollTaxesUnderCARESAct
118060
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
446941
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
119713
CY2020Q4 myo Accrued Liabilities Customer Deposit
AccruedLiabilitiesCustomerDeposit
300
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
494531
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3949784
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2848904
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21805
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
63.0000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17581
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.4700
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Options Adjustment Due To Reverse Stock Split In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentDueToReverseStockSplitInPeriod
28
CY2020 myo Share Based Compensation Arrangements By Share Based Payment Award Options Adjustments Due To Reverse Stock Split Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentsDueToReverseStockSplitWeightedAverageExercisePrice
63.0000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
123
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.0500
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2201
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
58.6600
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
421
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
80.5500
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24088
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.2900
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23194
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
9250
CY2021 myo Share Based Compensation Arrangements By Share Based Payment Award Options Adjustments Due To Reverse Stock Split Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentsDueToReverseStockSplitWeightedAverageExercisePrice
17.0700
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1174
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
50.9600
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
439
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.0500
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
31725
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.5800
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
14998
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
68.0300
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11894
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
17390
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
63.2600
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12392
CY2021 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2020 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.32
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.73
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.1190
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.1014
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0054
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1096408
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
614302
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
181176
CY2019Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
181176
CY2019Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
86.40
CY2019Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
86.40
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2694823
CY2020 myo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
2694823
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
7.46
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePriceExercisable
7.46
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
48005
CY2020 myo Class Of Warrant Or Rights Expired
ClassOfWarrantOrRightsExpired
48005
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice
198.98
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePriceExercisable
198.98
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
-118835
CY2020 myo Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
-118835
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice
1.36
CY2020 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable
1.36
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2709159
CY2020Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
2709159
CY2020Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
7.77
CY2020Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
7.77
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
273
CY2021 myo Class Of Warrant Or Rights Expired
ClassOfWarrantOrRightsExpired
273
CY2021 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice
194.10
CY2021 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePriceExercisable
194.10
CY2021 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
-2015243
CY2021 myo Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
-2015243
CY2021 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice
7.40
CY2021 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable
7.40
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
693643
CY2021Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
693643
CY2021Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
8.76
CY2021Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
8.76
CY2021 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
25900
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
175900
CY2020Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
44900
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
112900
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
457200
CY2020Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
29600
CY2021 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company has a non-cancelable lease agreement for its corporate headquarters in Boston, MA expiring in 2023, and it has a non-cancelable lease agreement for its office space in Fort Worth, TX expiring in 2025 with early termination available at the company’s discretion in 2023. Termination options were not included in the lease term for the Company's existing operating lease. Certain of the arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
633000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
735000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2548000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2548000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
454774
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
312014
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
57852
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
59459
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
884099
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
149097
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
735002
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
333380
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
401622
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
735002
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
372114
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
9072
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
29759
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
631433
CY2021 us-gaap Lease Cost
LeaseCost
401873
CY2020 us-gaap Lease Cost
LeaseCost
640505
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.20
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.20
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2580000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
88928
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2580000
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
119713
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
81981
CY2021 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
79142
CY2020 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
61752
CY2021 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
26735
CY2021 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
49309
CY2020 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
24020
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
176281
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
119713
CY2020 myo Number Of Customers
NumberOfCustomers
1
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10494693
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-11552483
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
211292
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-11428
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10283401
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11563911
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2038000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2065000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-510000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-515000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
88928
CY2021 myo Federal State And Local And Foreign Income Tax Expense Benefit
FederalStateAndLocalAndForeignIncomeTaxExpenseBenefit
-2459072
CY2020 myo Federal State And Local And Foreign Income Tax Expense Benefit
FederalStateAndLocalAndForeignIncomeTaxExpenseBenefit
-2580000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0521
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0557
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
0.0136
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
-0.0048
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies Domestic
EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
-0.0079
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0086
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0279
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0299
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2478
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2231
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0086
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16067000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13761000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
311000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
158000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
27000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
28000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
648000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
558000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17053000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14505000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17053000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14505000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2021Q4 myo Operating Loss Carry Forwards Annual Limitations
OperatingLossCarryForwardsAnnualLimitations
281000
CY2021Q4 myo Operating Loss Carryforwards Unutilized
OperatingLossCarryforwardsUnutilized
437000
CY2021Q4 myo Deferred Tax Asset And Valuation Allowance Adjusted To Reflect Federal Nol Unutilized
DeferredTaxAssetAndValuationAllowanceAdjustedToReflectFederalNOLUnutilized
92000

Files In Submission

Name View Source Status
0001564590-22-009827-index-headers.html Edgar Link pending
0001564590-22-009827-index.html Edgar Link pending
0001564590-22-009827.txt Edgar Link pending
0001564590-22-009827-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
myo-10k_20211231.htm Edgar Link pending
myo-10k_20211231_htm.xml Edgar Link completed
myo-20211231.xsd Edgar Link pending
myo-20211231_cal.xml Edgar Link unprocessable
myo-20211231_def.xml Edgar Link unprocessable
myo-20211231_lab.xml Edgar Link unprocessable
myo-20211231_pre.xml Edgar Link unprocessable
myo-ex1027_191.htm Edgar Link pending
myo-ex1028_192.htm Edgar Link pending
myo-ex1029_193.htm Edgar Link pending
myo-ex211_11.htm Edgar Link pending
myo-ex231_9.htm Edgar Link pending
myo-ex311_7.htm Edgar Link pending
myo-ex312_8.htm Edgar Link pending
myo-ex321_10.htm Edgar Link pending
myo-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending